Curiosity is only vanity. We usually only want to know something so that we can talk about it. ― Blaise Pascal
It has been a challenging six months for shareholders of biotech stalwart Celgene (CELG). The stock as can be seen below has been a poor performer in the overall market. The company and its shares have been hit by a series of trial disappointments and worries about whether a major pipeline asset will see eventual FDA approval.